GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Consun Pharmaceutical Group (HKSE:01681) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Jun. 09, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Consun Pharmaceutical Group's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Consun Pharmaceutical Group's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Consun Pharmaceutical Group's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Consun Pharmaceutical Group's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


Consun Pharmaceutical Group  (HKSE:01681) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Consun Pharmaceutical Group Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Consun Pharmaceutical Group (HKSE:01681) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
HKSE:06896 HKSE:02877 HKSE:02348 HKSE:01061 HKSE:02552 HKSE:06600 HKSE:00460 HKSE:02633 HKSE:03737 HKSE:01652 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
C1P:Germany
Address
71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Website
https://www.chinaconsun.com
Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Executives
An Yubao 2101 Beneficial owner
Li Qian 2101 Beneficial owner
Central Success Developments Limited 2101 Beneficial owner
Aali Resources Limited 2201 Interest of corporation controlled by you
Bos Trustee Limited 2301 Trustee
Zhang Lihua 2202 Interest of your spouse
An Meng 2101 Beneficial owner
Double Grace International Limited 2101 Beneficial owner
Bos Trustee Limited As Trustee 2201 Interest of corporation controlled by you

Consun Pharmaceutical Group (HKSE:01681) Headlines

No Headlines